Cancer drug discovery through collaboration

Nature Reviews Drug Discovery

Volumn 4, Issue 5, 2005, Pages 375-380

  Lengauer, Christoph ^b   Diaz Jr , Luis ^b   Saha, Saurabh ^a  

^a MCKINSEY AND COMPANY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CLOFARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; OXALIPLATIN; PEMETREXED; RETINOIC ACID; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BIOTECHNOLOGY; CANCER GENETICS; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPETENCE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC DISORDER; GENOMICS; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; COOPERATIVE BEHAVIOR; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 18944395185     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1722     Document Type: Article

References (29)

1. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
2. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350, 2129-2132 (2004).
3. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
4. Patel, J. D., Pasche, B. & Argiris, A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Critical Rev. Oncol. Hematol. 50, 175-186 (2004).
5. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
6. Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451-456 (2004).
7. Tolchin, E. Pharmaceutical giants fund start-ups. Drug Discov. Devel. 2, 22 (2004).
8. Association of University Technology Managers, Inc. (Lori Pressman, ed.) AUTM Licensing Survey. A Survey Summary of Technology Licensing (and Related) Performance for U. S. and Canadian Academic and Nonprofit Institutions, and Patent Management Firms. Northbrook, IL, USA, 2003.
9. Edwards, M., Murray, F. & Yu, R. Value creation and sharing among universities, biotechnology and pharma. Nature Biotechnol. 21, 618-624 (2003).
10. Department of Health and Human Services. NIH response to the conference report request for a plan to ensure taxpayers' interests are protected [online], http://www.nih.gov/news/070101wyden.htm (2001).
11. Shreefal, M. The emerging role of academia in commercializing innovation. Nature Biotechnol. 22, 21-24 (2004).
12. The NIH Almanac [online], http://www.nih.gov/about/almanac/index.html (2003).
13. Leaf, C. Why we're losing the war on cancer - and how to win it. Fortune 76f (22 March 2004).
14. Booth, B. & Zemmel, R. Quest for the best. Nature Rev. Drug Discov. 2, 838-841 (2003).
15. Garber, K. US NHGRI launches chemical attack on drug development gap. Nature Biotechnol. 21, 1253-1254 (2003).
16. Austin, C. P., Brady, L. S., Insel, T. R. & Collins, F. S. NIH Molecular Libraries Initiative. Science 306, 1138-1139 (2004).
17. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
18. Pollack, A. UCSD getting more involved in drug trials. SignOnSanDiego.com [online], http://www.signonsandiego.com/news/business/biotech/ 20030731-9999_1b31biotech.html (31 July 2003).
19. MIT Press Release. Novartis opens drug research center in MIT's Tech Square [online], http://web.mit.edu/newsoffice/2002/novartis.html (6 May 2002).
20. Smaglik, P. Boston: a magnetic hub. Naturejobs 417, 4-5 (2002).
21. Schwarz, K. & Iquin, J. T. Building the translational highway: toward new partnerships between academia and the private sector. Nature Med. 9, 493-495 (2003).
22. Mallik, A., Zbar, B. & Zemmel, R. Making pharma alliances work. The McKinsey Quarterly 1 (2004).
23. Zavoico, G. B. A new culture of drug discovery. NIBR Science (Fall 2004).
24. Arnst, C. Cancer superdrugs, costly side effects. BusinessWeek 44-46 (21 June 2004).
25. Sawyers, C. L. Research on resistance to cancer drug Gleevec. Science 294, 1834 (2001).
26. Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nature Rev. Drug Discov. 2, 609-610 (2003).
27. Beyond the blockbuster drug. Strategies for nichebuster drugs, targeted therapies and personalized medicine. Business Insights (February 2005).
28. Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161-165 (2005).
29. CMR International 2003 R&D Compendium, Epsom, UK, 32 (March 2003).